BioSpace News Archive

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2020, after the market close on Wednesday, October 28, 2020.

The prevailing unhealthy food habits and hectic lifestyle of consumers across the world are the primary drivers of the global migraine drugs market.

Beta-hydroxybutyrate testing is used as the mainstay in the diagnosis of diabetic ketoacidosis and other ketonic states.

The global antiseptic and disinfectant market is expanding owing to with increasing number of infectious diseases across the globe.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, October 27, 2020 at 5pm ET to discuss third quarter 2020 financial results and provide a corporate update.

This is the company’s 6th FDA clearance and further solidifies its leadership as the most comprehensive acute AI vendor in the market

Noveome Biotherapeutics, Inc ., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the publication of preclinical results for Amnion-derived Multipotent Progenitor Cells (AMP cells) in the journal Neurotherapeutics . These new, peer-reviewed results demonstrate, for the first

AQC Dust is announcing the first American deployment of the Maximed, an innovative aerosol pathogen aspirator developed in response to the COVID-19 pandemic. Operating like a vacuum system, Maximed eliminates at the source the particles and aerosols exhaled by patients being treated in operating rooms, reducing the probability of contaminat

Robotic technology and automation currently assist healthcare professionals with patient care, medical research, surgical procedures, and more. The popularity of robotic technology appears to be on the rise with continued growth into the future, which may prove to be beneficial for healthcare institutions looking to promote their services to new consumers during the final quarter of the financial year.

Crown Aesthetics , a division of Crown Laboratories, Inc. and pioneers in advanced aesthetics solutions, sheds light on their dedication to patients’ safety following the decision to move all production of ProGen PRP TM , their FDA 510k cleared Platelet Rich Plasma system, to a manufacturing facility in the United States as of December